Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Keane (Los Angeles, United States of America). The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases. Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases

Member's Comments

No comment yet.

Related content which might interest you: The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 PAH and inflammation: its role in pathogenesis - is it of value to modulate it? Source: Annual Congress 2005 - Challenges in the biological understanding of pulmonary arterial hypertension Year: 2005 Pulmonary vascular involvement in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 28S-32S Year: 2003 Role of anti-proliferative therapy in PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Involvement of FHL1 in vascular remodelling Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 Neurokinins contribute to vascular remodelling in a model of chronic pulmonary allergic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 760s Year: 2006 Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction Source: Eur Respir J 2008; 31: 1334-1356 Year: 2008 Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Increased endothelial and epithelial apoptosis play a central role in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 The role of CX3CL1 and ADAM17 in pathogenesis of diffuse parenchymal lung diseases Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021 MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009 Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases Source: Eur Respir J 2008; 32: 1068-1081 Year: 2008 Inflammation in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 358-363 Year: 2003 FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018 Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 IL-11 promotes pulmonary vascular remodeling and lung fibrosis through the activation of endothelial to mesenchymal transition. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015